Latest news and press releases about MeiraGTx Holdings plc (MGTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers.
Price
| Price | $12.76 |
| Market Cap | $1.2B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 15.53 |
| Price / Book | 5.01 |
| EV / EBITDA | 4.49 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 284.38% |
| Return on Invested Capital | 52.45% |
| Return on Assets | 19.92% |
| Gross Margin | 97.19% |
| Operating Margin | 46.30% |
| Net Margin | 19.87% |
Explore sector: Healthcare · Biotechnology
More sections of MGTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks